Article ID Journal Published Year Pages File Type
6087427 Clinical Immunology 2015 8 Pages PDF
Abstract

•Antibody production against GAA is delayed during anti-BAFF immunotherapy.•Anti-BAFF protects against ERT-related anaphylaxis.•Delayed antibody production is associated with increased GAA activity in tissues.•Continued BAFF blockade prevents the formation and migration of GAA-specific plasmablasts into the bone marrow.

Antibodies formed against the therapeutic protein are a life-threatening complication that arises during enzyme replacement therapy for Pompe disease (acid α-glucosidase deficiency; GAA). To provide an effective alternative to current practices, we investigated the capacity of anti-B-cell activating factor (BAFF) as a novel drug candidate to prevent antibody formation in a Pompe disease mouse model. A BAFF-neutralizing antibody was administered prophylactically and with maintenance doses in association with enzyme replacement therapy using recombinant human GAA in Gaa−/− mice. BAFF blockade delayed antibody production and increased GAA activity within tissues with protection from anaphylaxis. Anti-BAFF also resolved antibody formation during an immune response and precluded the maturation of antibody secreting cells from entering the bone marrow compartment. This treatment modality may therefore be a viable alternative for the clinical management of antibody formation for Pompe disease and has potential use against antibody formation in other protein replacement therapies.

Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , ,